Adult stem cell banks to regenerate delicate hearts

Publié le : 31 January 2014

 The American Food and Drug Administration (FDA) has just given the Belgian biopharmaceutical company, Cardio3 BioSciences, the go-ahead to carry out a phase III clinical trial to test C-Cure treatment in 240 patients. This treatment which uses adult stem cells "represents the most advanced work in the field of cell therapies for heart diseases". It could be launched on the market in 2016 and might dispense with the need for transplantation. 

C-Cure is the fruit of research conducted by Professors André Terzic and Atta Behfar, at the Mayo Clinic University in Minnesota. This so-called autologous therapy can eliminate the risks of immune rejection. 
To administer this therapy, scientists have collected adult stem cells from the patient’s own bone marrow, from the hip, and have then "programmed then in vitro to become cardiac cell lines". They actually "reproduce protein signals, which, in an embryo, allow cells to differentiate themselves into the cells of a specific organ". The cells obtained to repair hearts "can then be injected into the myocardium using a specially developed catheter".  

Share this article

BIOETHICS PRESS SYNTHESIS